Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Downgraded by BidaskClub

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday.

A number of other research firms have also commented on VNDA. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $21.33.

Shares of Vanda Pharmaceuticals (NASDAQ VNDA) traded up 0.487% during mid-day trading on Friday, reaching $15.475. The company’s stock had a trading volume of 48,444 shares. The firm has a 50-day moving average of $16.17 and a 200-day moving average of $14.69. The firm’s market capitalization is $694.18 million. Vanda Pharmaceuticals has a 52 week low of $11.58 and a 52 week high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The business had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. During the same quarter last year, the business earned $0.01 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities research analysts forecast that Vanda Pharmaceuticals will post ($0.52) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Downgraded by BidaskClub” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2801712/vanda-pharmaceuticals-inc-nasdaqvnda-downgraded-by-bidaskclub.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc raised its position in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the period. Virginia Retirement Systems ET AL purchased a new position in Vanda Pharmaceuticals during the first quarter worth approximately $193,000. Capital Fund Management S.A. purchased a new position in Vanda Pharmaceuticals during the first quarter worth approximately $195,000. Dynamic Technology Lab Private Ltd purchased a new position in Vanda Pharmaceuticals during the first quarter worth approximately $196,000. Finally, AQR Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth approximately $223,000. Hedge funds and other institutional investors own 91.42% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.